Prasugrel holds up against clopidogrel in second Japanese study
This article was originally published in Scrip
Following the first filing in Japan last month for prasugrel hydrochloride, Daiichi Sankyo has released results from another of the local Phase III trials it is using to support the planned approval of the oral antiplatelet agent.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.